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Objective: To determine how much physical activity, in the form of walking, can be safely and feasibly
tolerated for people with severe knee osteoarthritis (OA).
Design: Phase I dose response trial with escalating walking doses of 10, 20, 35, 50, 70, and 95 min over
1 week, were prescribed non-randomly to people with severe knee OA. The primary stopping rule was a
substantial increase in knee pain. The primary outcomes were an estimation of the maximum tolerated
dose of walking; and the proportion of people who did not complete the dose for feasibility reasons. The
secondary outcomes were pain, stiffness and activity limitation Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC).
Results: Twenty-four participants (13 women) aged 53e83 years, and average body mass index (BMI) of
34 kg/m2 (SD 9) were recruited. Three participants were assigned to each dose between 10 and 70 min,
and nine participants assigned to the 95-min dose. The trial was stopped at 95 min due to the maximum
number of adverse events occurring at this dose. Therefore, the maximum tolerated dose was 70 min. No
participant stopped due to reasons related to feasibility. There was a moderate association between dose
and increased activity (linear R2 ¼ 0.31, cubic R2 ¼ 0.69) and reduced stiffness (linear R2 ¼ 0.20, cubic
R2 ¼ 0.52), with increased beneﬁts at moderate to higher doses.
Conclusions: There is preliminary evidence that 70 min per week of moderate intensity supervised
walking was safe and feasible for people with severe OA of the knee; for higher doses there was a risk of
exacerbating knee pain levels.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Increasing physical activity is important for people with osteo-
arthritis (OA) of the knee as their risk of mortality from cardio-
vascular causes is substantially increased1. Physical activity is
deﬁned as any bodily movement produced by the skeletal muscles
that requires energy expenditure including recreational tasks as
well as structured activities like exercise and is categorised intoo: J.A. Wallis, Physiotherapy
ustralia. Tel: 61-3-9895-3463
au, jasonwallis23@gmail.com
ternational. Published by Elsevier Llight, moderate and vigorous intensity2. Physical activity guidelines
for older adults recommend at least 150 min per week of at least
moderate physical activity in a minimum of 10 min bouts3. Main-
taining these levels of physical activity is associated with positive
health outcomes such as increased life expectancy and reduced
burden of major non-communicable diseases3. For people with
symptomatic knee OA aerobic exercise programs, which could
include walking programs, are recommended in clinical guidelines
to reduce pain and disability4e6. However, no speciﬁc guidelines
regarding a safe and effective dosage of walking are available for
people with severe knee OA. For people with mobility restrictions
due to the pain and disabilities associated with knee OA, guidelines
suggest these people be as physically active as their condition al-
lows3. Such recommendations create uncertainty for healthtd. All rights reserved.
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to their patients.
We recently completed a systematic review that found about
one in 10 people with knee OA met current physical activity
guidelines7. While physical activity programs for people with OA
are recommended4e6,8e12 physical activity levels remain low in this
population. One issue is that we do not know if the dosage rec-
ommended in physical activity guidelines3 is safe and applicable for
walking for people with severe knee OA. Therefore, investigation of
the highest dose that can be tolerated would provide information
that could inform guidelines.
To our knowledge a phase I dose response trial has not been
investigated previously in people with knee OA where the safety
proﬁle of a physical activity intervention, such as walking, can
determine the highest dose that can be tolerated (maximum
tolerated dose) without adverse events13. An adverse event is
deﬁned as any unfavourable and unintended sign, symptom, or
disease temporally associated with the use of an intervention or
procedure that may or may not be considered related to the
intervention or procedure14. Possible short-term adverse events
from increased levels of physical activity are temporary exacerba-
tions of pain12. Pain is a common symptom in people with knee
OA15 and may be due to sensitised peripheral nociceptors, and this
continuous nociceptive input may drive central sensitisation and
increased pain response16. While this pain response does not
necessarily indicate a worsening of the osteoarthritic condition,
substantial increases in pain may lead to modiﬁcations to physical
activity17.
In the systematic review7 we also found that people with knee
OA may not be much less physically active compared to people of
similar age without OA. One interpretation of these results is that a
low level of physical activity is not solely related to disease factors
such as pain, but could also be related to non-disease factors, such
as demographic, physical, social, psychological and environmental
factors18. Therefore it is not known if it is feasible for people with
knee OA to complete recommended doses of physical activity.
Therefore the primary research questions of the present study
were: How much physical activity, in the form of walking, can be
safely tolerated for people with severe knee OA? How feasible is it
for people with severe knee OA in the community to complete
doses of physical activity, in the form of walking? The secondary
research question was to determine if there is a doseeresponse
relationship for a change in pain, stiffness and activity limitation?
Method
Study design
In this phase I doseeresponse study, an algorithm based (A þ B)
design13,19,20 was used. The ﬁrst cohort of three participants
received the same dose. If no participant stopped due to an adverse
event, the second cohort of three participants received the next
higher dose and so on. However, if a participant stopped due to an
adverse event, the second cohort of three participants was pre-
scribed the same dose as the ﬁrst cohort. If no further adverse
events occurred the study continued at the next higher dose.
However if another adverse event occurred the dose escalation
stopped at that level and the previous dose was considered as the
maximum tolerated dose (Fig. 1).
If any participant elected to stop due to reasons related to
feasibility, the next participant was recruited and received the same
dose. For the purpose of this study, a lack of feasibility was deﬁned
as not completing the walking dose due to reasons other than
safety. For example a participant may not have completed the
walking dose due to unexpected time pressures.The health service and university ethics committees approved
this trial in accordance with the Helsinki Declaration and all par-
ticipants provided written informed consent. The trial was regis-
tered in the Australian New Zealand Clinical Trials Registry http://
www.ANZCTR.org.au/ACTRN12614000098639.aspx.
Participants
Adults with OA of the knee were recruited consecutively from a
metropolitan health service's OA hip and knee clinic between
January and April 2014. Patients who attended the service were
invited to participate provided theymet the inclusion criteria: adult
aged at least 50 years and living independently in the community;
diagnosed with unilateral or bilateral severe knee OA rated as grade
III or IV determined radiographically21; participants with contra-
lateral knee replacement and unilateral severe knee OA in
remaining intact limb were eligible; able to understand English;
able to participate safely in the moderate-intensity physical activity
trial according to the 7-item Physical Activity Readiness
Questionnaire22.
Participants were excluded if they: lived in supported accom-
modation such as a nursing home; reported daily resting level of
pain to be 9 or 10 on a 0 (no pain) to 10 (worst possible pain)
Numerical Pain Rating Scale23. This level of pain may be indicative
of a more serious pathology; had very high levels of psychological
distress as measured by the Kessler 10 questionnaire with a score
>2924; had an intellectual impairment as measured by the Short
Portable Mental Status Questionnaire with a score of 7 or less25;
had a systemic arthritic condition such as rheumatoid arthritis; had
a neurological condition that affected walking; had knee surgery or
intra-articular corticosteroid injection within the past 6 months;
had used oral corticosteroids within 4 weeks.
Dose prescription
Physical activity, in the form of walking, was chosen because of
the importance of this type physical activity to health outcomes for
people with OA1. Thewalking doses of 10, 20, 35, 50, 70, 95, 120 and
150 min over 1 week, of at least moderate intensity, in a minimum
of 10 min sessions were selected so the doses could be compared
with the current physical activity guidelines (Table I). Participants
were aware the dose was between 10min and 150 min over 1 week
prior to participation. The initial dose of 10min per weekwas based
on data from previous research that found a relatively high pro-
portion (49%) of people with knee OA did not complete any bouts of
physical activity at a moderate intensity for at least 10 min26. The
dose levels then approximated a modiﬁed Fibonacci scheme27. For
the maximum dose, the current physical activity guideline was
selected as only a small proportion (10%) of people with knee OA
met this guideline26.
The participants completed thewalking doses in the community
using normal assistive devices, such as a walking stick. Each
walking sessionwas supervised individually by a physiotherapist to
ensure any adverse events were managed appropriately and the
dose was completed. The number of walking sessions to complete
the walking dose was planned and agreed through discussion be-
tween the physiotherapist and the participant. For example the 50-
min dose could include 2 15minwalking sessions and 1 20min
session over 3 days. Participants were instructed to walk at a
moderate intensity of three using the Rate of Perceived Exertion
scale (0e10) and cadence monitored to ensure it was greater than
80 steps/minute28. Participants continued taking their usual med-
ications to manage their knee OA. To reduce the risk of adverse
events due to other physical activities, participants who were
currently participating in physical activity of moderate intensity in
Fig. 1. Phase 1 dose response trial, 3 þ 3 design.
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activity for 2 days prior to and during the test period. For example,
physical activities like brisk walking or cycling were avoided.
However, light everyday activities did not need to be avoided or
modiﬁed.
Outcomes
The primary outcomes were: An estimation of the maximum
tolerated dose of walking for people with severe knee OA; and the
proportion of people with severe knee OA who did not complete
the walking dose for feasibility reasons.
The secondary outcomes were: Pain, stiffness and activity lim-
itation using the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC)29. The participants completed the
WOMAC questionnaire at two times: day 1 prior to the ﬁrst walking
session; and day 7 after completion of the walking dose.
The following factors were collected to describe the partici-
pants: Age, gender, body mass index (BMI), severity of knee OA
including the compartments affected21, presence of knee deformity
using clinical observation, co-morbidities, medication use, physical
activity level using the Incidental and Planned ActivityTable I
Walking doses
Dose Minutes per week Intensity Increment
1 10 Moderate e
2 20 Moderate 100%
3 35 Moderate 75%
4 50 Moderate 43%
5 70 Moderate 40%
6 95 Moderate 35%
7 120 Moderate 26%
8 150 Moderate 25%Questionnaire (IPAQWA)30, and physical activity measures of
cadence, number of steps, distance covered and walking speed
during each walking bout measured using an electronic pedometer
worn by the participant (iPhone 4S: Footsteps, developed by Palm
Shadow Apps LLC, http://palmshadow.com/index.php).
Participants were followed up for 7 days after their ﬁrst bout of
walking. This period was selected to monitor any potential adverse
effects from completing the walking dose; any potential adverse
effects would be expected to have occurred by this time.Stopping rules e adverse events
A stopping rule was deﬁned as an adverse event or incident that
stopped the participant from completing the walking dose for
safety reasons and was likely related to the dose.
Stopping rule 1: Substantial knee pain levels during a walking
session.
Knee pain levels were recorded for each walking session, using
the 0 to 10 point Numerical Pain Rating Scale23, at the beginning, at
5-min intervals during, immediately on completion, and at 2 h after
completion when resting. A participant who reported their knee
pain level during the walk as unchanged or decreased compared
with the beginning pain level would be expected to complete the
walk. A participant who reported their knee pain level had
increased during the walk but the level was less than 7/10 would be
expected to complete the walk. A participant who reported their
knee pain level had increased during the walk and the level was at
least 7/10 were asked, “Are you prepared to continue?” This
participant could continue or stop. Participants who stopped were
expected to retry the walk on a subsequent day and the same rules
were applied. If they stopped again, an adverse event was deemed
to have occurred.
Stopping rule 2: Substantial knee pain levels after a walking
session.
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completion of a walking session relative to the beginning knee pain
level resulted in stopping the dose due to safety reasons. Sub-
stantial increases in painwas deﬁned as resting knee pain of at least
7/10 2 h after the walk which had increased by at least 3/10 if the
pain level was between 0 and 6 at the beginning of the walk, or had
increased by at least 2/10 if the pain level was 7e8 at the beginning
of the walk. The thresholds of 3/10 and 2/10 were based on data
that suggests that 2/10 represents a clinically signiﬁcant change in
pain and varies depending on the initial level31. If a participant
reported to the investigator a substantial amount of pain more than
2 h after the walk the dose was stopped and the participant was
assisted to health professional management as appropriate.
Stopping rule 3: Serious adverse events.
If any participant reported difﬁculty breathing that did not settle
quickly with rest, new or unrelenting chest pain, or acute change in
conscious level during the activity, this may precede a serious
medical emergency such as cardiac arrest or stroke32. In this event
the session was stopped immediately with immediate emergency
response. A potentially serious event was if the participant reported
difﬁculty breathing but symptoms settled quickly with rest and
their clinical signs (respiration rate, heart rate, oxygen saturation)
remained normal. This participant could elect to complete the dose
provided these symptoms settled quickly with rest and clinical
signs remained normal.
Data analysis
The estimation of sample size was based on the algorithm based
design and dose escalation19 whereby a maximum 48 participants
(eight dose levels with at maximum six patients, not including
participants that stop due to feasibility). As it was hypothesised the
maximal tolerated dose would be between doses four and six, the
expected sample size was between 21 and 45 participants.
The primary analysis determined the maximum tolerated dose
in minutes of moderate intensity walking per week (Fig. 1)19. The
primary analysis of feasibility was based on the proportion of
participants not able to complete the walking dose for feasibility
reasons.
The secondary analyses were performed using IBM SPSS Sta-
tistics 21 and a P-value <0.05 was considered statistically signiﬁ-
cant. Parametric tests were reported because parametric tests are
relatively robust to minor violations of normality, and the results
are easily interpretable by other researchers. Associations between
the walking dose and baseline participant characteristics of age,
BMI, resting pain level, psychological distress (Kessler 10) and usual
physical activity level (IPAQWA) were explored using Pearson's
correlation coefﬁcient, r, to check for any bias in dose allocation. To
test for a dose response relationship, associations between the
walking dose, and changes in pain, stiffness and activity limitations
over 7 days (WOMAC) were explored using linear and non-linear
modelling. For the maximum tolerated dose or less, average knee
pain levels recorded after completion of the walking sessions were
compared to the beginning level of pain using paired t tests. Finally,
physical activity parameters associated with the maximum toler-
ated dose were reported.
Results
After screening 89 potentially eligible participants, 24 partici-
pants (13 women, 11 men) aged between 53 and 83 years, with an
average BMI of 34 kg/m2 (SD 9) met the selection criteria (Fig. 2). All
participants had severe knee OAwith 23 participants (96%) rated as
grade IV and one participant (4%) rated as grade III using Kell-
greneLawrence scale21. Fifteen of the 24 subjects had bilateralsevere knee OA and nine of the 24 subjects had unilateral severe
knee OA. Two of the 24 subjects had a contralateral knee replace-
ment. On average, participants self-reported participating in 2 h per
week (SD 2 h) of planned physical activities such as home exercises
and exercise classes. Seven participants (29%) self-reported no
planned physical activity per week.
The most common comorbidities were hypertension (n ¼ 11),
and high cholesterol (n ¼ 11). There were no signiﬁcant associa-
tions between the walking dose and baseline participant charac-
teristics of age (r ¼ .05), BMI (r ¼ .11), resting knee pain (r ¼ .27),
Kessler 10 score (r ¼ .06) and total physical activity (r ¼ .18).
Table II summarises participants' characteristics.Maximum tolerated dose and adverse events
For the ﬁrst 5 walking doses (10e70 min), none of the 15 par-
ticipants had adverse events (Table III). There was a small increase
in average knee pain level at the immediate completion of each
walking bout compared to the knee pain level at the beginning of
each bout (mean increase ¼ 2.1 units, 95% CI ¼ 1.0, 3.2); and knee
pain level settled at 2 h rest to levels comparable to knee pain level
at the beginning of each bout (mean increase ¼ 0.3 units, 95%
CI ¼ 0.9, 1.4).
For the 95-min walking dose, one of the ﬁrst three participants
did not complete the dose due to an adverse event. Of the next
three participants prescribed the 95-min dose, one participant had
an adverse event. After discussion between the investigators it was
decided that a further three participants be prescribed the 95 min
dose. Of the ﬁnal three participants, one participant had an adverse
event. Therefore three out of nine participants prescribed 95 min
had an adverse event, all reporting substantial pain levels after 2 h
rest as per stopping rule 2. Therefore, the maximum tolerated dose
was 70min of walking over 1week, at moderate intensity in at least
10-min bouts. Therewere no serious adverse events from any of the
participants (Table III).Minor adverse events
Four participants reported minor adverse events that were not
considered a stopping event. One participant had an episode of
momentary unsteadiness that resolved immediately; two partici-
pants stopped brieﬂy during a walking session to rest their knee
momentarily; one participant reported moderate hip pain that
settled after each walk.Feasibility
No participant stopped the dose of walking due to reasons of
feasibility.Dose response
For the 15 participants completing up to the level of the
maximum tolerated dose of 70 min, and who provided day 1 and
day 7 WOMAC scores (n ¼ 13), linear modelling indicated no as-
sociation between dose and changes in pain (R2 ¼ 0.01), and a
moderate association between dose and improved activity
(R2 ¼ 0.31) and reduced stiffness (R2 ¼ 0.20). Non-linear modelling
estimated U-shaped dose response curves suggesting a moderate
dose might be associated with a reduction in pain (cubic R2¼ 0.32),
activity limitation (cubic R2 ¼ 0.69) and stiffness (cubic R2 ¼ 0.52)
(Fig. 3).
Fig. 2. Trial recruitment proﬁle.
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For the maximum tolerated dose of 70 min per week (n ¼ 3),
7138 steps (SD 208) and 4770 m (SD 1185) were covered during the
supervised sessions at a cadence of 99 steps per minute (SD 2.7)
and average walking speed of 1.1 m/s (SD 0.23).Discussion
This phase I dose response trial with escalating dose demon-
strated up to 70 min per week of moderate intensity walking, in at
least 10-min sessions, in addition to baseline physical activity
associated with daily life, was tolerated for people with severe knee
OA. For higher doses, adverse events occurred with knee pain levels
that increased to severe levels during thewalk and remained severe
for at least 2 h after the event.
For the 15 participants who completed up to the maximum
tolerated dose of 70 min, those who completed higher doses of
walking did not experience increases in pain intensity at the end of
the week compared to people who completed lower doses. While
increased dynamic loading can predict progression of radiographic
knee OA33,34, the preliminary ﬁndings in the current study are
consistent with evidence that dynamic knee loading may not pre-
dict changes in pain intensity35. Linear modeling also provided
preliminary evidence that higher doses were associated with less
limitation to daily activities and less knee stiffness; and non-linear
modeling provided preliminary evidence suggesting the greatest
beneﬁts may have been observed with moderate doses of walking.
Conﬁdence bands around these estimates were wide suggesting
uncertainty about the dose response in this small sample. While
these effects were seen over 1 week, it remains to be tested
whether a repeated weekly dose for people with severe knee OAwill demonstrate sustained positive changes to activity and pain
levels.
The results of our study may assist people with severe knee OA
to feel more conﬁdent of engaging in physical activity, and poten-
tially beneﬁt from a more active lifestyle. A previous study showed
an association between negative pain perceptions by people with
OA to be associated with physical and psychological disability36
which may prevent people with knee OA from engaging in
walking. Pain catastrophising, which is the tendency to focus on
andmagnify pain sensations, was found to have an associationwith
physical disability36. Moreover, pain related fear, which is the fear
of re-injury due to movement, was also found to have an associa-
tion with psychological disability36. Our results suggest that in the
short term people with severe knee OA are capable of completing
70 min of moderate intensity walking in bouts of at least 10 min
tolerating knee pain levels that settle quickly with rest.
While 70 min per week was safely tolerated for participants
with severe knee OA this level of physical activity is less than half
the level recommended in physical activity guidelines for older
people3. The question remains if this dosage is sufﬁcient to provide
longer term health beneﬁts, such as reduced risk of cardiovascular
disease that is associated with inactivity and is a notable concern
for people with OA1. People without OA who exercise for 15 min a
day have a 14% reduced risk of all-cause mortality and a 3-year
longer life expectancy compared to those who are inactive37.
Therefore the results for people without OA suggests there may be
relevant health beneﬁts from prescribing 70 min per week for
people with severe knee OA, in addition to their usual physical
activity. Further research investigating the medium term outcomes
about reducing cardiovascular risk factors and long term outcomes
about survival is warranted.
The results of the current study are consistent with ﬁndings that
a pre-operative intervention that primarily focuses on increasing
Table II
Participant characteristics
10 min (n ¼ 3) 20 min (n ¼ 3) 35 min (n ¼ 3) 50 min (n ¼ 3) 70 min (n ¼ 3) 95 min (n ¼ 9) All participants (n ¼ 24)
Age (yrs)
Mean (SD) 65 (11) 70 (7) 68 (7) 66 (12) 67 (15) 66 (6) 67 (8)
Range [minemax] [53e74] [62e76] [61e75] [55e78] [53e83] [57e76] [53e83]
Sex, n (%) women 3 (100) 1 (33) 0 (0) 2 (67) 1 (33) 6 (67%) 13 (54)
BMI (kg/m2)
Mean (SD) 33 (7) 29 (4) 38 (2) 29 (8) 40 (19) 34 (9) 34 (9)
Range [minemax] [27e40] [25e32] [36e39] [21e37] [26e62] [24e48] [21e62]
OA score*
n (%) grade IV 3 (100) 3 (100) 3 (100) 2 (67) 3 (100) 9 (100) 23 (96)
n (%) grade III 0 (0) 0 (0) 0 (0) 1 (33) 0 (0) 0 (0) 1 (4)
Unilateral or bilateral knee OA
n (%) unilateral knee OA 2 (33) 1 (33)k 1 (33) 1 (33) 1 (33) 3 (33)k 9 (37)k
n (%) bilateral knee OA 1 (67) 2 (67) 2 (67) 2 (67) 2 (67) 6 (67) 15 (63)
Main knee compartments affected by OA
n (%) medial 2 (67) 2 (67) 3 (100) 3 (100) 3 (100) 7 (78) 20 (83)
n (%) medial and patellofemoral 1 (33) 1 (33) 0 (0) 0 (0) 0 (0) 0 (0) 2 (8)
n (%) lateral 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (22) 2 (8)
Presence of knee deformity (mild)
n (%) varus ± ﬁxed ﬂexion 1 (33) 3 (100) 2 (67) 2 (67) 2 (67) 5 (56) 15 (63)
n (%) valgus ± ﬁxed ﬂexion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (22) 2 (8)
n (%) ﬁxed ﬂexion only 1 (33) 0 (0) 0 (0) 1 (33) 1 (33) 1 (11) 4 (17)
n (%) nil deformity 1 (33) 0 (0) 1 (33) 0 (0) 0 (0) 1 (11) 3 (13)
Kessler 10y (10e50)
Mean (SD) 18 (4) 17 (6) 14 (2) 11 (1) 15 (9) 17 (5) 16 (5)
Range [minemax] [14e21] [12e24] [13e16] [10e12] [10e26] [12e25] [10e26]
Physical activity e incidental (hours/week)
Mean (SD) 28 (15) 25 (16) 26 (19) 18 (4.3) 29 (23) 20 (14) 23 (14)
Range [minemax] [11e41] [15e44] [8e46] [13e22] [14e56] [7e46] [7e56]
Physical activity e planned (hours/week)
Mean (SD) 5 (2) 3 (1) 0.8 (1) 0.5 (0.9) 0.4 (0.7) 2 (3) 2 (2)
Range (minemax) [3e7] [2e5] [0e2] [0e2] [0e1] [0e8] [0e8]
Physical activity e totalz (hours/week)
Mean (SD) 32 (17) 28 (16) 27 (20) 18 (5) 30 (23) 23 (16) 25 (15)
Range [minemax] [15e48] [18e46] [8e48] [13e22] [14e56] [7e53] [7e56]
WOMACx pain (0e20)
Mean (SD) 8 (2) 11 (3) 10 (2) 7 (4) 7 (7) 10 (3) 9 (4)
Range [minemax] [7e10] [9e14] [8e11] [3e9] [0e14] [5e14] [0e14]
WOMAC stiffness (0e8)
Mean (SD) 4 (2) 4 (2) 4 (1) 3 (2) 4 (2) 5 (2) 4 (2)
Range [minemax] [3e5] [3e6] [4e5] [2e6] [2e5] [0e7] [0e7]
WOMAC activity limitation (0e68)
Mean (SD) 18 (10) 36 (8) 35 (3) 23 (9) 26 (21) 37 (13) 31 (13)
Range [minemax] [11e30] [30e45] [32e38] [14e31] [2e43] [11e59] [2e59]
Single point stick, n (%) 0 (0) 0 (0) 1 (33) 1 (33) 0 (0) 4 (44) 6 (25)
* OA score rated using KellgreneLawrence scale14.
y Kessler 10 score: 10e15 low, 16e21 moderate, 22e29 high, 30e50 very high level of psychological distress.
z Total physical activity in hours per week is the sum of incidental physical activity (e.g., housework, gardening or walking to the shops) AND planned physical activity (e.g.,
walking for exercise, home exercises or exercise classes).
x WOMAC pain: 0 (best) to 20 (worst); stiffness: 0 (best) to 8 (worst); activity limitation: 0 (best) to 68 (worst).
k Two participants with unilateral knee OA had a contralateral TKA.
Table III
Adverse events
10 min (n ¼ 3) 20 min (n ¼ 3) 35 min (n ¼ 3) 50 min (n ¼ 3) 70 min (n ¼ 3)* 95 min (n ¼ 9) All doses (n ¼ 24)
Adverse events 0 0 0 0 0 3y 3y
Serious adverse events 0 0 0 0 0 0 0
* Maximum tolerated dose.
y Substantial pain levels after walking.
J.A. Wallis et al. / Osteoarthritis and Cartilage 23 (2015) 1285e12931290levels of physical activity through walking may be safe, feasible and
has the potential to be more beneﬁcial compared to mixed pre-
operative group program38. A recent systematic review and meta-
analysis of 48 randomised controlled trials found programs for
people with OA that focused on one type of exercise was more
beneﬁcial in reducing pain and patient reported disability
compared to exercise programs that used mixed types of exercises
with different exercise goals within the same session39. With long
wait times for joint replacement surgery, the maximum tolerateddose of walking for people with severe knee OA may be an exercise
option for people with severe knee OA.
The strength of our study was by applying a method that is
typically used for testing the safety proﬁle of a drug, to prescribing
physical activity to peoplewith OA, which to our knowledge has not
been done before. There are a number of limitations in our study.
First, as part of the 3 þ 3 phase I trial design, the estimate of the
maximum tolerated dose is discontinuous and imprecise, but it
could not fall outside the pre-speciﬁed dose levels. Second, we
Fig. 3. Figure 3a: Linear and non-linear dose response relationships (95% CI) for change in pain (WOMAC) after completion of the walking dose (a negative score indicates a decrease
in pain), Figure 3b: Linear and non-linear dose response relationships (95% CI) for change in activity limitation (WOMAC) after completion of the walking dose (a negative score
indicates a decrease in activity limitation). Figure 3c: Linear and non-linear dose response relationships (95% CI) for change in stiffness (WOMAC) after completion of the walking
dose (a negative score indicates a decrease in stiffness).
J.A. Wallis et al. / Osteoarthritis and Cartilage 23 (2015) 1285e1293 1291included a relatively small sample of participants and limited the
dose to 1 week. However, our results from this phase I trial can
inform planning for a phase II/III randomised controlled trial
design, on a larger number of participants over a longer time period
to test its efﬁcacy. Third, the recruitment method and allocation of
doses was at risk of selection bias as it was not randomised.
However there was no association between the walking doses and
the baseline characteristics. Fourth, we did not monitor partici-
pant's background physical activity level during the week when
they completed their walking dose. Finally, the adverse events were
measured subjectively with self-reported pain levels, whereas in
drug trials adverse events can be measured objectively using
toxicity levels in the blood. However, there are no objective bio-
logical markers for the presence of pain and self-report is the most
accurate and reliable evidence of measuring pain and its intensity31.Conclusion
There is preliminary evidence that 70min per week of moderate
intensity supervised walking was safe and feasible for people withsevere OA of the knee. For higher doses there was a risk exacer-
bating knee pain levels.
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